SOL Capital Management CO decreased its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 35.6% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 52,032 shares of the biopharmaceutical company's stock after selling 28,814 shares during the period. SOL Capital Management CO's holdings in Pfizer were worth $1,318,000 at the end of the most recent reporting period.
A number of other large investors also recently bought and sold shares of the stock. Rialto Wealth Management LLC purchased a new position in Pfizer in the fourth quarter valued at approximately $26,000. Clarity Asset Management Inc. purchased a new position in shares of Pfizer in the 4th quarter valued at $27,000. Gould Capital LLC lifted its holdings in shares of Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 493 shares in the last quarter. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Pfizer during the 4th quarter valued at $28,000. Finally, Bernard Wealth Management Corp. purchased a new stake in Pfizer during the 4th quarter worth $30,000. Hedge funds and other institutional investors own 68.36% of the company's stock.
Wall Street Analysts Forecast Growth
A number of brokerages have commented on PFE. Guggenheim restated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. UBS Group boosted their price target on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. Citigroup restated a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. The Goldman Sachs Group reiterated a "neutral" rating and set a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Finally, Cantor Fitzgerald initiated coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 target price for the company. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have given a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $29.17.
Read Our Latest Research Report on PFE
Pfizer Stock Down 0.2%
Shares of NYSE:PFE traded down $0.04 during midday trading on Friday, reaching $24.20. The company had a trading volume of 39,502,107 shares, compared to its average volume of 41,288,221. The stock has a market capitalization of $137.56 billion, a P/E ratio of 17.53, a PEG ratio of 0.88 and a beta of 0.57. The stock's fifty day moving average price is $23.42 and its 200-day moving average price is $24.85. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54.
Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.25. The company had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The firm's revenue for the quarter was down 7.8% compared to the same quarter last year. During the same period last year, the business earned $0.82 EPS. Equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.
Pfizer Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.11%. The ex-dividend date is Friday, July 25th. Pfizer's dividend payout ratio (DPR) is presently 124.64%.
About Pfizer
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Further Reading
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
